Abstract

CAGIDE, Arturo. Evolution of treatment of heart failure. Insuf. card. [online]. 2015, vol.10, n.1, pp.49-55. ISSN 1852-3862.

Heart failure (HF) is considered a common ultimate goal of many of the most prevalent diseases, such as: arterial hypertension, coronary disease, diabetes mellitus, valvular heart disease, etc., added to the problems and comorbidities own group elderly. Moreover, few drugs also have been shown to be effective in improving survival of patients with this disease. Only, therapies that induce a neurohormonal blockade (such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone blocking and beta blockers) reduced mortality. In the last 15 years, there have been numerous attempts to find a new drug option, but at the end proved unsuccessful. Is it possible pharmacological intervention by simultaneously blocking the renin-angiotensin-aldosterone system, and raise the level of natriuretic hormones? LCZ696 is a pharmaceutical formulation in a single molecule that incorporates two active substances: valsartan (angiotensin receptor blocker) and sacubitril (neprilysin inhibitor), increasing to 40% bioavailability compared to their single administration. Since in the treatment of heart failure, enalapril is the standard intervention, confirm the probable superiority of LCZ696 over the former would have greater clinical relevance, as it shares the same basic mechanism of action. In conclusion, this new drug reduced mortality in moderate HF, and did so in a clinically significant extent. Over conventional treatment, almost 1.5 more lives are avoided for every 100 patients treated annually. The benefit is enhanced obviously with fewer hospitalizations, better living standards and greater social inclusion.

Keywords : Heart failure; Neurohormonal blockade; LCZ696.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )